Recent Advances in Nanotherapeutics for Neurological Disorders

Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side- effects, and immune responses in neurodegenerative diseases is essential for developing better therapies. The immune activation in a diseased state has complex treatment protocols and results in hurdles for clinical translation. There is an immense need for the development of multifunctional nanotherapeutics with various properties to address the different limitations and immune interactions exhibited by the existing therapeutics. Nanotechnology has proven its potential to improve therapeutic delivery and enhance efficacy. Promising advancements have been made in developing nanotherapies that can be combined with CRISPR/Cas9 or siRNA for a targeted approach with unique potential for clinical translation. Engineering natural exosomes derived from mesenchymal stem cells (MSCs), dendritic cells (DCs), or macrophages to both deliver therapeutics and modulate the immune responses to tumors or in neurodegenerative disease (ND) can allow for targeted personalized therapeutic approaches. In the present review, we summarize and overview the recent advances in nanotherapeutics in addressing the existing treatment limitations and neuroimmune interactions for developing ND therapies and provide insights into the upcoming advancements in nanotechnology-based nanocarriers.

[1]  M. Nair,et al.  Multi-functional auto-fluorescent nanogels for theranostics , 2023, Journal of NeuroVirology.

[2]  N. Thorat,et al.  Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics , 2023, ACS biomaterials science & engineering.

[3]  N. Voelcker,et al.  A Multifunctional Porous Silicon Nanocarrier for Glioblastoma Treatment. , 2022, Molecular pharmaceutics.

[4]  Ki‐Bum Lee,et al.  Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials. , 2022, Advanced drug delivery reviews.

[5]  Xinmei Wang,et al.  Exosomes—Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics , 2022, ACS nano.

[6]  Michał M Kłosowski,et al.  Nanostars Carrying Multifunctional Neurotrophic Dendrimers Protect Neurons in Preclinical In Vitro Models of Neurodegenerative Disorders , 2022, ACS applied materials & interfaces.

[7]  S. Kannan,et al.  Dendrimer-siRNA Conjugates for Targeted Intracellular Delivery in Glioblastoma Animal Models. , 2022, ACS applied materials & interfaces.

[8]  F. Ferrari,et al.  Development of alginate-spermidine micro/nanogels as potential antioxidant and anti-inflammatory tool in peripheral nerve injuries. Formulation studies and physico-chemical characterization. , 2022, International journal of pharmaceutics.

[9]  M. Suar,et al.  Emerging trends in the nanomedicine applications of functionalized magnetic nanoparticles as novel therapies for acute and chronic diseases , 2022, Journal of Nanobiotechnology.

[10]  Haiyan Liu,et al.  Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics , 2022, Frontiers in bioengineering and biotechnology.

[11]  Yaolin Xu,et al.  Brain Tumor Imaging and Delivery of Sub-5 nm Magnetic Iron Oxide Nanoparticles in an Orthotopic Murine Model of Glioblastoma , 2022, ACS Applied Nano Materials.

[12]  S. Murugesan,et al.  Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases , 2022, Heliyon.

[13]  Yuan-Lu Cui,et al.  Hydrogen bond-enhanced nanogel delivery system for potential intranasal therapy of Parkinson's Disease , 2022, Materials & Design.

[14]  M. Nair,et al.  Recent advances, status, and opportunities of magneto-electric nanocarriers for biomedical applications. , 2021, Molecular aspects of medicine.

[15]  Ying Zheng,et al.  Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies , 2021, Theranostics.

[16]  Y. Loh,et al.  Function of exosomes in neurological disorders and brain tumors , 2021, Extracellular Vesicles and Circulating Nucleic Acids.

[17]  Hui Xie,et al.  Dual-responsive biohybrid neutrobots for active target delivery , 2021, Science Robotics.

[18]  N. Voelcker,et al.  Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges , 2021, Advanced science.

[19]  S. Sacanna,et al.  Modulation of Immune Responses by Particle Size and Shape , 2021, Frontiers in Immunology.

[20]  Lixiang Wang,et al.  Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment , 2021, Drug delivery.

[21]  Anjali Sharma,et al.  Targeting Mitochondria in Tumor-Associated Macrophages using a Dendrimer Conjugated TSPO Ligand Stimulates Anti-Tumor Signaling in Glioblastoma. , 2020, Biomacromolecules.

[22]  Jonghan Kim,et al.  Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes. , 2020, Molecular pharmaceutics.

[23]  M. Nair,et al.  Development of Multifunctional Biopolymeric Auto-Fluorescent Micro- and Nanogels as a Platform for Biomedical Applications , 2020, Frontiers in Bioengineering and Biotechnology.

[24]  S. Kannan,et al.  Dendrimer size effects on the selective brain tumor targeting in orthotopic tumor models upon systemic administration , 2020, Bioengineering & translational medicine.

[25]  Sanjay Arora,et al.  Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes , 2020, Brain Research.

[26]  Raghu Kalluri,et al.  The biology, function, and biomedical applications of exosomes , 2020, Science.

[27]  J. Ljubimova,et al.  Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Anjali Sharma,et al.  Dense hydroxyl polyethylene glycol dendrimer targets activated glia in multiple CNS disorders , 2020, Science Advances.

[29]  D. G. Parambi,et al.  Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives , 2019, The Journal of pharmacy and pharmacology.

[30]  Hongzhuan Chen,et al.  Harnessing Exosomes for the Development of Brain Drug Delivery Systems. , 2019, Bioconjugate chemistry.

[31]  S. M. Dizaj,et al.  Applications of nanotechnology in drug delivery to the central nervous system. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  A. Anel,et al.  Role of Exosomes in the Regulation of T-Cell Mediated Immune Responses and in Autoimmune Disease , 2018, Cells.

[33]  Ling Zhang,et al.  Dopamine‐loaded blood exosomes targeted to brain for better treatment of Parkinson's disease , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Xiaoyuan Chen,et al.  Aptamer‐based targeted therapy , 2018, Advanced drug delivery reviews.

[35]  M. Sawan,et al.  Colloidal stability of superparamagnetic iron oxide nanoparticles in the central nervous system: a review. , 2018, Nanomedicine.

[36]  C. Dispenza,et al.  Nose‐to‐brain delivery of insulin enhanced by a nanogel carrier , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[37]  M. Chopp,et al.  Exosomes Derived from Mesenchymal Stromal Cells Promote Axonal Growth of Cortical Neurons , 2016, Molecular Neurobiology.

[38]  S. Kannan,et al.  Nanoscale effects in dendrimer-mediated targeting of neuroinflammation. , 2016, Biomaterials.

[39]  K. Ulbrich,et al.  Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. , 2016, Chemical reviews.

[40]  C. Dispenza,et al.  Ionizing radiation-engineered nanogels as insulin nanocarriers for the development of a new strategy for the treatment of Alzheimer's disease. , 2016, Biomaterials.

[41]  O. Abdallah,et al.  Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity. , 2015, Journal of pharmaceutical sciences.

[42]  F. Borràs,et al.  Therapeutic Potential of Extracellular Vesicles , 2014, Front. Immunol..

[43]  Abeer M. Al-Ghananeem,et al.  Intranasal Drug Delivery of Olanzapine-Loaded Chitosan Nanoparticles , 2014, AAPS PharmSciTech.

[44]  R. Vassar,et al.  Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation , 2013, Molecular Neurodegeneration.

[45]  York Winter,et al.  Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline , 2012, Nature Medicine.

[46]  D. Dickson,et al.  Massive gliosis induced by interleukin‐6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  G. Brewer,et al.  Age‐ and concentration‐dependent neuroprotection and toxicity by TNF in cortical neurons from β‐amyloid , 2001, Journal of neuroscience research.

[48]  W. Griffin,et al.  Microglial inter leukin‐1α expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution , 1995, Neuropathology and applied neurobiology.